TABLE 5.
Incidence of pulmonary irAEs in hematological malignancies.
| Pneumotoxicity | ||||||
| Author | Condition | Phase | Regimen | Symptom | Incidence | |
| all grade | grade ≥ 3 | |||||
| Armand et al. (2021) | RR cHL, NHL, MM | 1b | nivo + ipili | pneumonitis | 12% | 5% |
| nivo + liri | 1% | 0% | ||||
| Diefenbach et al. (2020) | RR cHL | 1/2 | ipili + BV | pneumonitis | 4% | 0% |
| nivo + BV | 10% | 10% | ||||
| ipili + nivo + BV | 5% | 0% | ||||
| Davids et al. (2016) | RR hematol. malign. | 1/1b | ipili | pneumonitis | 11% | 4% |
| Bashey et al. (2009) | cancer post HSCT | 1 | ipili | pneumonitis | 7% | 7% |
| Maruyama et al. (2020) | RR cHL | 2 | nivo | IST lung disease | 24% | 6% |
| pneumonitis | 12% | 0% | ||||
| Bröckelmann et al. (2020) | ND cHL | 2 | nivo + AVD | pneumonitis | 1% | 0% |
| Armand et al. (2018a) | RR cHL | 2 | nivo | pneumonitis | 4% | 0% |
| Herrera et al., 2018 | RR cHL | 1/2 | nivo + BV | pneumonitis | NA | 3% |
| Lesokhin et al. (2016) | RR hematol. malign. | 1b | nivo | pneumonitis | 11% | 4% |
| Khodadoust et al. (2016) | RR MF, RR SS | 2 | pembro | pneumonitis | 8% | 4% |
| Barta et al. (2019) | RR T-NHL | 2 | pembro | pneumonitis | 11% | 11% |
| Armand et al. (2019) | RR PMBL | 2 | pembro | pneumonitis | 2% | 2% |
| Armand et al. (2016) | RR cHL | 1b | pembro | pneumonitis | 10% | 0% |
| Liu et al. (2021) | RR cHL | 2 | camre | pneumonitis | 5% | 5% |
| camre + decitabine | 5% | 0% | ||||
| Mei et al. (2020) | RR PMBL | 2 | camre + GVD | pneumonitis | 7% | 4% |
| Usmani et al. (2019) | ND MM | 3 | pembro + lena + dex | pneumonitis | 1% | 0% |
| Ribrag et al. (2019) | RR MM | 1b | pembro | upper respir. tract inf. | 3% | 0% |
| Mateos et al. (2019a) | RR MM | 3 | pembro + pom + dex | pneumonitis | 3% | 1% |
| Badros et al. (2017) | RR MM | 2 | pembro + pom + dex | pneumonitis | 13% | 2% |
| Zeidan et al. (2018) | RR MDS | 1b | ipili | pneumonitis | 3% | 0% |
| Davids et al. (2020) | RR hematol. malign. | 1 | nivo | pneumonitis | 14% | 4% |
| Daver et al. (2019) | RR AML | 2 | nivo + azacitidine | pneumonitis | 13% | 1% |
RR, relapsed/refractory; ND, newly diagnosed; cHL, classical Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; MM, multiple myeloma; PMBL, primary mediastinal large B cell lymphoma; DLBCL, diffuse large B cell lymphoma; MF, mycosis fungoides; SS, Sézary syndrome; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; HSCT, (allogeneic) hematopoietic stem cell transplantation; ipili, ipilimumab; liri, lirilumab; nivo, nivolumab; BV, brentuximab vedotin; AVD, adriamycin + vinblastine + dacarbazine; GVD, gemcitabine + vinorelbine + doxorubicin; pembro, pembrolizumab; pom, pomalidomide; dex, dexamethasone; ida, idarubucin; camre, camrelizumab; IST, interstitial.